Gilead brings five-year pediatric Biktarvy data to AIDS 2026
The oral presentation extends a fixed-dose HIV regimen already approved for adults into a long-running pediatric study, with five years of follow-up data due at the July 26-31 conference.
Executive Summary
- Gilead will present five-year follow-up data from a long-running pediatric study of its fixed-dose bictegravir combination at the AIDS 2026 conference, extending evidence for an adult-approved regimen into children and adolescents.
- The study enrolled its full target across four cohorts spanning toddlers through adolescents, with the primary completion date having slipped repeatedly over nearly a decade before enrollment closed at target in late 2024.
- The regimen is already the standard fixed-dose oral option in HIV treatment for adults, so the pediatric readout tests durability and safety in younger, lower-weight patients rather than opening a new efficacy question.
- The pediatric extension sits inside a field where multiple integrase and reverse-transcriptase inhibitors already hold pediatric-adjacent development programs, so the value of this data lies in reinforcing an established regimen's reach rather than differentiating a new mechanism.
The presentation
Gilead Sciences said it will present five-year results from NCT02881320, a study of its bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in adolescents and children with HIV-1, as an oral presentation at the 26th International AIDS Conference, running July 26-31, 2026, in Rio de Janeiro. The company's announcement grouped the pediatric update alongside other HIV research it plans to present at the conference, including long-term follow-up from its Phase 3 lenacapavir prevention trials. Jared Baeten, the company's senior vice president of clinical development for its virology therapeutic area, said the data reflect Gilead's ongoing commitment to HIV treatment and cure research. GileadGilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and CureJul 21, 2026
The trial itself
NCT02881320 is an interventional, open-label study spanning Phase 2 and Phase 3, testing pharmacokinetics and safety of the three-drug combination across four cohorts defined by age and weight, from adolescents 12 to under 18 down to children as young as one month old. The trial enrolled 177 participants, its full target, across sites in the United States, South Africa, Thailand, and Uganda. It started in September 2016 and has been Active, not recruiting since October 30, 2024, when enrollment closed at target. NCT02881320Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1NCT02881320
A long operational arc
The trial's primary completion date moved six times over its history, from an original target of July 2020 to a final primary completion of March 24, 2025, a cumulative delay of roughly four and a half years. The trial briefly re-entered active recruitment in February 2023 after previously reporting Active, not recruiting status, with its enrollment target rising from 122 to 172 that same month before settling at 177 by October 2024. That enrollment growth reflects the trial's design of adding younger, lower-weight cohorts over time rather than a shortfall against an original target; the study closed with its full target reached. NCT02881320Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1NCT02881320
Where this sits in the field
Bictegravir is already approved as part of Biktarvy for treating HIV-1 infection in adults and pediatric patients weighing at least 14 kg, so the AIDS 2026 data tests whether that established efficacy and safety profile extends to younger and lighter children, including the sub-14-kg cohort enrolled in this trial. The nearest mechanism comparator in active development is Gilead's own bictegravir/lenacapavir combination study in children and adolescents, NCT06532656, which is not due to complete until 2030, while ViiV Healthcare's cabotegravir and Merck's islatravir and doravirine programs remain concentrated in adult HIV-1 populations. Integrase-inhibitor development in HIV-1 overall remains active, with 26 ongoing trials studying the target in this indication, even as broader field activity in HIV-1 integrase research has declined sharply from its historical peak.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.